We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

Join the live Q&A on PrEP, the latest in HIV prevention. Text your questions to 713-526-1111 and tune in Monday to learn ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

A new HIV drug, lenacapavir, appears highly effective against strains circulating in Uganda, according to a study led by ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.

A multi-national, multi-institutional study investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda.

A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...

Twice-yearly lenacapavir PrEP could be available as early as this summer pending federal Food and Drug Administration ...

At the State of Black Health second annual summit hosted by BlackDoctor.org in partnership with USA TODAY, corporate leaders discussed health equity.